Food and Drug Administration
AM
Session
Celgene Corporation Briefing
Material
The statements
contained in this document(s) are not those of the FDA, and FDA does not
necessarily agree with these statements.
FDA has not made a final determination about the issues to be discussed at
the Advisory Committee meeting.
Revlimid® (lenalidomide) briefing material
Food and
Drug Administration
Portions
of these documents may have been determined to be exempt from disclosure under
the Freedom of Information Act (the FOIA) (5 U.S.C. §552)
These redacted portions will appear
as white space on the screen or on the printed page.
FDA Revlimid® Briefing Material
PM
Session
GlaxoSmithKline
Briefing Material
The
statements contained in this document(s) are not those of the FDA, and FDA does
not necessarily agree with these statements.
FDA has not made a final determination about the issues to be discussed at
the Advisory Committee meeting.
Arranon®
(nelarabine) Injection Briefing Material
Food and Drug Administration
Disclaimer
Portions
of these documents may have been determined to be exempt from disclosure under
the Freedom of Information Act (the FOIA) (5 U.S.C. §552)
These redacted portions will appear
as white space on the screen or on the printed page.